

RECEIVED  
CENTRAL FAX CENTER

JUL 17 2006

PATENT

DOCKET NO.: ISIS-5203  
Application No.: 10/700,920  
Restriction Requirement Mailed: June 26, 2006

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of  
**Brenda F. Baker, et al.**  
Application No.: 10/700,920  
Filing Date: November 4, 2003  
For: **Oligomeric Compounds Having Modified Bases For Binding To Cytosine And Uracil Or Thymine And Their Use In Gene Modulation**

Confirmation No.: 7522

Group Art Unit: 1635

Examiner: Tracy Ann Vivlemore

I certify that this correspondence is being facsimile transmitted or is being deposited with the U.S. Postal Service as First Class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

On July 17, 2006  
Pamela Grooms

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

## RESPONSE TO THE RESTRICTION REQUIREMENT

The present response is filed in regard to the Restriction Requirement mailed June 21, 2006 in connection with the above-identified patent application.

- Amendments to the Specification** begin on page \_\_\_\_\_ of this paper.
- Amendments to the Claims** are reflected in the listing of the claims which begins on page \_\_\_\_\_ of this paper.
- Amendments to the Drawings** begin on page \_\_\_\_\_ of this paper and include an attached replacement sheet.
- Remarks** begin on page 13 of this paper.

RECEIVED  
CENTRAL FAX CENTER

JUL 17 2006

DOCKET NO.: ISIS-5203  
Application No.: 10/700,920  
Restriction Requirement Mailed: June 26, 2006

PATENT

**RESPONSE TO THE RESTRICTION REQUIREMENT**

In response to the Restriction Requirement mailed June 26, 2006 in connection with the above-identified patent application. Applicants elect Group I, containing claims 1-32 and 35-64. Applicants further elect the species of group 3), claim 13. Claims 1-10, 13, 35-42, 45 and 64 are readable on the elected species.

DOCKET NO.: ISIS-5203  
Application No.: 10/700,920  
Restriction Requirement Mailed: June 26, 2006

PATENT

**Conclusion**

It is believed all of the claims presently before the Examiner patentably define the invention over the prior art and are otherwise in condition for ready allowance. An early Office Action to that effect is, therefore, earnestly solicited.

Respectfully submitted,

Robert S. Andrews

Date: June 1, 2006

Robert S. Andrews

Registration No. 44,508

Isis Pharmaceuticals, Inc.

1896 Rutherford Road

Carlsbad, CA 92008

Telephone: (760) 603-2352

Facsimile: (760) 603-3820